Target intelligence / Profile preview

Low affinity immunoglobulin gamma Fc region receptor II-b (FCGR2B)

Target
FCGR2B
Molecular classification
Receptor
01

Overview

Low affinity immunoglobulin gamma Fc region receptor II-b (FCGR2B, also known as CD32B) is a type I transmembrane glycoprotein and the sole inhibitory receptor within the Fc gamma receptor (FcγR) family. It is widely expressed on B cells, dendritic cells, macrophages, and other myeloid cells, where it plays a critical role in maintaining immune homeostasis and preventing autoimmunity. Upon co-engagement with the B-cell receptor (BCR) or activating Fc receptors by immune complexes, FCGR2B undergoes phosphorylation of its cytoplasmic immunoreceptor tyrosine-based inhibition motif (ITIM), recruiting phosphatases like SHIP1/2 to downregulate cell activation, antibody production, and phagocytosis.

In oncology, high expression of FCGR2B on tumor cells is associated with resistance to monoclonal antibody therapies (such as rituximab) by promoting antibody internalization and degradation. Consequently, therapeutic strategies targeting FCGR2B include antagonistic antibodies (e.g., BI-1206, BI-1607) to overcome drug resistance in B-cell malignancies and solid tumors, as well as bifunctional antibodies (e.g., obexelimab) that co-engage CD19 and FCGR2B to suppress B-cell activity in autoimmune and inflammatory diseases.

Other names
CD32BCD32CDw32Fc gamma receptor IIBFc-gamma-RIIbFcRII-bFCG2IGFR2Fc fragment of IgG low affinity IIb receptor
02

Mechanism of action

Monoclonal antibodies targeting FCGR2B (CD32B) act either as antagonists to block its inhibitory signaling, thereby enhancing the efficacy of other therapeutic antibodies (such as rituximab or pembrolizumab) by preventing target internalization and restoring antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP), or as bifunctional agents (e.g., co-targeting CD19) that co-engage the B-cell receptor complex and FCGR2B to trigger intracellular ITIM-mediated inhibitory pathways (via SHIP1/2 recruitment) and suppress B-cell activation without depleting the cells.

03

Biological functions

Immune responseSignal transductionApoptosisOther
04

Disease associations

CancerInflammationOther
05

Safety considerations

Infusion-related reactionsThrombocytopeniaElevated liver enzymesRisk of autoimmunity or exacerbated inflammatory responses due to systemic blockade of inhibitory signaling
06

Interacting drugs

2 more in the full profile.

07

Biomarkers

FCGR2B expression levelCD32B expression levelFCGR2B promoter polymorphismsFCGR2B Ile232Thr polymorphism

Beyond the preview

Go deeper on Low affinity immunoglobulin gamma Fc region receptor II-b (FCGR2B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Low affinity immunoglobulin gamma Fc region receptor II-b (FCGR2B).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call